Search

Author/Creator Spigel, David R

1. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Issue 5 (May 2017)

Authors:
Gulley, James L; Rajan, Arun; Spigel, David R; Iannotti, Nicholas; Chandler, Jason; Wong, Deborah J L; Leach, Joseph; Edenfield, W Jeff; Wang, Ding; Grote, Hans Juergen; Heydebreck, Anja von; Chin, Kevin; Cuillerot, Jean-Marie; Kelly, Karen
Journal:
Lancet oncology
Issue:
Volume 18:Issue 5(2017:May)
Page Start:
599
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Issue 7 (July 2017)

Authors:
Shaw, Alice T; Kim, Tae Min; Crinò, Lucio; Gridelli, Cesare; Kiura, Katsuyuki; Liu, Geoffrey; Novello, Silvia; Bearz, Alessandra; Gautschi, Oliver; Mok, Tony; Nishio, Makoto; Scagliotti, Giorgio; Spigel, David R; Deudon, Stéphanie; Zheng, Cheng; Pantano, Serafino; Urban, Patrick; Massacesi, Crist...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 7(2017:Jul.)
Page Start:
874
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings. (19th February 2022)

Authors:
Sturgill, Emma G; Misch, Amanda; Jones, Carissa C; Luckett, Daniel; Fu, Xiaotong; Schlauch, Dan; Jones, Suzanne F; Burris, Howard A; Spigel, David R; McKenzie, Andrew J
Journal:
Oncologist
Issue:
Volume 27:Number 3(2022)
Page Start:
175
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. Issue 2 (1st February 2023)

Authors:
Ready, Neal E; Audigier-Valette, Clarisse; Goldman, Jonathan W; Felip, Enriqueta; Ciuleanu, Tudor-Eliade; Rosario García Campelo, María; Jao, Kevin; Barlesi, Fabrice; Bordenave, Stéphanie; Rijavec, Erika; Urban, Laszlo; Aucoin, Jean-Sébastien; Zannori, Cristina; Vermaelen, Karim; Arén Frontera, O...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 11:Issue 2(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Issue 9 (September 2021)

Authors:
Javle, Milind; Borad, Mitesh J; Azad, Nilofer S; Kurzrock, Razelle; Abou-Alfa, Ghassan K; George, Ben; Hainsworth, John; Meric-Bernstam, Funda; Swanton, Charles; Sweeney, Christopher J; Friedman, Claire F; Bose, Ron; Spigel, David R; Wang, Yong; Levy, Jonathan; Schulze, Katja; Cuchelkar, Vaikunth...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 9(2021)
Page Start:
1290
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Issue 4 (April 2019)

Authors:
Meric-Bernstam, Funda; Hurwitz, Herbert; Raghav, Kanwal Pratap Singh; McWilliams, Robert R; Fakih, Marwan; VanderWalde, Ari; Swanton, Charles; Kurzrock, Razelle; Burris, Howard; Sweeney, Christopher; Bose, Ron; Spigel, David R; Beattie, Mary S; Blotner, Steven; Stone, Alyssa; Schulze, Katja; Cuch...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 4(2019)
Page Start:
518
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Issue 1 (January 2017)

Authors:
Rudin, Charles M; Pietanza, M Catherine; Bauer, Todd M; Ready, Neal; Morgensztern, Daniel; Glisson, Bonnie S; Byers, Lauren A; Johnson, Melissa L; Burris, Howard A; Robert, Francisco; Han, Tae H; Bheddah, Sheila; Theiss, Noah; Watson, Sky; Mathur, Deepan; Vennapusa, Bharathi; Zayed, Hany; Lally, ...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 1(2017:Jan.)
Page Start:
42
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. Issue 9 (14th September 2022)

Authors:
George, Daniel J; Spigel, David R; Gordan, Lucio N; Kochuparambil, Samith T; Molina, Ana M; Yorio, Jeff; Rezazadeh Kalebasty, Arash; McKean, Heidi; Tchekmedyian, Nishan; Tykodi, Scott S; Zhang, Joshua; Askelson, Margarita; Johansen, Jennifer L; Hutson, Thomas E
Journal:
BMJ open
Issue:
Volume 12:Issue 9(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗